9 Results for "

Capan 1

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "Capan 1" in MCE Product Catalog:

Cat. No.: HY-155993
CAS No.: 3032451-66-1
Purity:  99.39%
Target:  

PARP

Research Areas:  

Cancer

YCH1899 is an orally active PARP inhibitor, with an IC50< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC50 values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats .
loading...
    loading...
Cat. No.: HY-168721
CAS No.: 63589-51-5
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Tubulin inhibitor 48 (compound 16) is an anti-cancer agent targeting tubulin. Tubulin inhibitor 48 has an IC50 of 0.1 and 0.07 μM for LN-229 and Capan-1 cell, respectively .
loading...
    loading...
Cat. No.: HY-155766
CAS No.: 2098639-70-2
Target:  

PARP Apoptosis

Research Areas:  

Cancer

PARP1-IN-14 (compound 19k) is a potent PARP1 inhibitor, with an IC50 of 0.6 ± 0.1 nM. PARP1-IN-14 exhibits antiproliferative effect against both MDA-MB-436 (BRCA1 −/−) and Capan-1 (BRCA2 −/−) cells with IC50 values below 0.3 nM .
loading...
    loading...
Cat. No.: HY-163715
Target:  

FAK

Research Areas:  

Cancer

Antitumor agent-165 (Compound 10l) is a potent focal adhesion kinase (FAK) inhibitor. Antitumor agent-165 exhibits effective antiproliferative activity against CAPAN-1, PANC-1, PATU-T, SUIT-2, BxPC-3, PDAC-3 and PANC-1 GR with IC50s in the range of 1.04-3.44 μM .
loading...
    loading...
Cat. No.: HY-163817
CAS No.: 3032451-58-1
Target:  

PARP

Research Areas:  

Cancer

PARP1/2-IN-3 (Compound 29) is an orally active inhibitor for PARP 1 and PARP 2 with IC50 of 0.2235 nM and <0.001 nM. PARP1/2-IN-3 inhibits the proliferation of Capan-1 wildtype, AZD2281 or BMN673 resistant cells with IC50 of 1.82-9.98 nM. PARP1/2-IN-3 exhibits antitumor efficacy in mice .
loading...
    loading...
Cat. No.: HY-14687
CAS No.: 1207454-56-5
Synonyms: (rac)-BMN-673; (rac)-LT-673
Target:  

PARP

Research Areas:  

Cancer

(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is the orally active inhibitor for PARP1/2 with Ki of 1.2 nM and 0.87 nM. (rac)-Talazoparib inhibits cellular PARylation with an EC50 of 2.51 nM. (rac)-Talazoparib causes the accumulation of DNA damage, inhibits proliferation of BRCA1/2-mutated MX-1 cell and Capan-1 cell with IC50 of 0.3 nM and 5 nM. (rac)-Talazoparib exhibits antitumor efficacy in mouse models .
loading...
    loading...
Cat. No.: HY-147101
CAS No.: 2523017-04-9
Target:  

PARP

Research Areas:  

Cancer

SK-575-NEG (compound 28), a methylation counterpart of SK-575, is synthesized by methylation of the amino group of piperidine-2,6-dione in SK-575 as an control compound. SK-575-NEG is strongly bound to PARP1, with an IC50 of 2.64 nM. SK-575-NEG was completely ineffective in inducing PARP1 degradation in MDA-MB-436 and Capan-1 cells at concentrations up to 1 μM .
loading...
    loading...
Cat. No.: HY-161934
Research Areas:  

Cancer

PARP1-IN-27 (Compound 9B) is the inhibitor for PARP1 and PARP2, with IC50 of 2.53 nM and 6.45 nM in cell SUM149PT. PARP1-IN-27 inhibits the proliferation of BRCA-mutated cancer cells SUM149PT, HCC1937 and Capan-1, with IC50 of 0.62, 1.91 and 4.26 μM respectively. PARP1-IN-27 aggravates DNA double-strand breaks, increases ROS generation, arrests cell cycle at G2/M phase, and induces apoptosis in SUM149PT .
loading...
    loading...
Cat. No.: HY-184967
Research Areas:  

Cancer

XZ8078 is a potent, selective dual-target PROTAC degrader against PARP1 and IKZF3. In Capan-1 cells, XZ8078 exhibits a DC50 of 23.01 nM for PARP1 degradation and a DC50 of 23.20 nM for IKZF3 degradation. XZ8078 upregulates DNA damage markers in a concentration-dependent manner, induces cell cycle arrest, upregulates activated caspases and triggers apoptosis. XZ8078 inhibits tumor growth in both AZD5305-sensitive and AZD5305-resistant xenograft models. XZ8078 can be used for cancer-related research .
loading...
    loading...